MEGIN

MEGIN is a global leader in magnetoencephalography (MEG) technology, providing non-invasive functional brain mapping solutions for clinical and research use. The company's flagship product, the TRIUX™ neo, offers real-time assessment of neural activity with millimeter accuracy and millisecond resolution, which is critical for presurgical evaluation in conditions like epilepsy and brain tumors. MEGIN's technology is also extensively used in research for neurodegenerative diseases, autism, and traumatic brain injury. Headquartered in Helsinki, Finland, the company has a global presence with over 100 systems installed worldwide. MEGIN was formerly the MEG business of Elekta and was acquired by York Instruments, a subsidiary of Croton Healthcare, in 2018.